Abbott Laboratories Stock Performance
Abbott Laboratories shares closed at $102.05, trading below both key moving averages, with the 50-day moving average at $105.58 and the 200-day moving average at $103.06, per SID market data. The stock has declined 8.29% over the past month and 17.24% over the trailing twelve months, though it has gained 15.07% over the past three months, suggesting a recent pullback within a medium-term recovery. The 14-day RSI stands at an extremely oversold 16.8, indicating significant near-term selling pressure that has pushed the stock well below conventional oversold thresholds. Abbott's beta of 0.751 reflects lower volatility relative to the broader market, consistent with its positioning in the healthcare sector. Average daily trading volume stands at approximately 8.88 million shares, according to Massive/Polygon data. The company's market capitalization currently sits at approximately $202.45 billion, maintaining its status as a large-cap healthcare name.
Abbott Laboratories Valuation Analysis
Abbott Laboratories trades at a price-to-earnings ratio of 31.15, reflecting a premium valuation relative to the broader market, per SID market data. The company's price-to-book ratio stands at 3.90, according to SEC filings, indicating investors are paying nearly four times book value for the healthcare conglomerate's assets. The PEG ratio registers at negative 0.58, which suggests that forward earnings growth estimates have turned negative, complicating traditional growth-adjusted valuation assessments. Abbott offers a dividend yield of 2.06%, providing income-oriented investors with a moderate return above the S&P 500 average yield. As a healthcare sector constituent, Abbott's valuation premium partly reflects the defensive characteristics and recurring revenue streams typical of diversified medical device and diagnostics companies. The current P/E multiple positions Abbott at a level that demands sustained earnings execution to justify the premium pricing relative to historical averages.
Smart Money Activity for ABT
Abbott Laboratories registers a smart money score of 51 out of 100, signaling a neutral overall stance among sophisticated market participants, per SID market data. Institutional ownership receives a perfect score of 25 out of 25, indicating robust participation from major fund managers and pension funds in holding ABT shares. In contrast, insider activity scores a modest 9.7 out of 25, with SEC Form 4 filings revealing 14 insider transactions over the past 90 days, evenly split between 7 purchases and 7 sales. This balanced insider trading pattern suggests no directional conviction among company executives and directors. Dark pool activity scores 8.5 out of 25, reflecting relatively subdued off-exchange institutional block trading. Congressional trading activity registers at 7.6 out of 25, according to 13F institutional filings and public disclosure records. The combination of strong institutional backing with mixed insider signals presents a balanced but inconclusive smart money picture for Abbott at current price levels.
Abbott Laboratories Earnings Outlook
Abbott Laboratories has demonstrated consistent earnings execution in recent quarters, according to company earnings reports. In the most recently reported quarter, Abbott posted earnings per share of $1.31, exceeding the consensus analyst estimate of $1.28 by $0.03, representing a positive surprise. The prior quarter also delivered a beat, with actual EPS of $1.15 versus the $1.14 estimate, a $0.01 positive surprise. Looking ahead, analyst estimates project EPS of $1.15 for the upcoming reporting period scheduled for April 15, 2026, and $1.42 for the October 2026 quarter, per analyst estimates. The sequential increase from $1.15 to an estimated $1.42 implies anticipated earnings acceleration through the fiscal year. Abbott's pattern of modest but consistent beats across consecutive quarters reflects disciplined operational management. The trajectory from $1.15 to $1.42 in estimated quarterly earnings represents approximately 23.5% sequential growth, suggesting analysts expect meaningful improvement in Abbott's profitability profile.
Wall Street Analyst Ratings for ABT
Wall Street consensus on Abbott Laboratories remains firmly bullish, with recent analyst actions uniformly reflecting positive sentiment, per Wall Street analyst reports. TD Cowen has reiterated its Buy rating on multiple occasions, including actions on September 8, August 25, and July 17, 2026, demonstrating sustained conviction in Abbott's fundamental trajectory. Notably, Wolfe Research upgraded ABT to Outperform from Peer Perform on August 13, 2026, representing the most significant rating change in recent coverage activity. UBS maintained its Buy rating on July 28, 2026, further reinforcing the bullish consensus. Across the five most recent analyst actions tracked by SID consensus data, zero downgrades have been issued, and the sole rating change was an upgrade. The clustering of Buy and Outperform ratings from major institutional brokerages suggests broad agreement regarding Abbott's competitive positioning within the healthcare sector. The absence of any Hold or Sell ratings among recent actions indicates strong institutional analyst confidence despite the stock's recent price weakness.
